Eurobio Scientific buys Dutch transplant diagnostics firm GenDx for €135 million

The Dutch HLA typing startup will continue its activities in both its Utrecht headquarters and its North American office, located in Chicago
Eurobio Scientific buys Dutch transplant diagnostics firm GenDx for €135 million

The Netherlands-based startup that offers molecular diagnostic kits Genome Diagnostics (GenDx) has been acquired by Paris-based Eurobio Scientific for €135 million. The acquisition will lead to the formation of a foundation to assist research and development in the field of transplantation.

GenDx will continue its activities in both its Utrecht headquarters and its North American office, located in Chicago. The GenDx portfolio will be continued and supported by its existing mature sales and global distributor network.

The Dutch human leukocyte antigen (HLA) typing company, which matches patients and donors for bone marrow or cord blood transplants, specialises in molecular diagnostics. Founded in 2005, it focuses on the development, production and sales of assays and analysis software for transplant and companion diagnostics.

Wietse Mulder, co-founder and CEO of GenDx said: “Eurobio is a good home for GenDx to secure the support of our customers in the field of transplant diagnostics and to align with our global distributor network. Furthermore, it will allow our employees to continue their superb work in R&D, operations, logistics, regulatory affairs, sales, marketing, support and, importantly, our renowned educational activities.”

Eurobio Scientific owns a broad and diversified portfolio of products in four specialty areas, including transplantation, infectious diseases, life science and cancer.

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.